CURA Diagnostics successfully participated in the 2026 conference hosted by the National Drug and Alcohol Screening Association, where the company officially launched its next-generation oral fluid (OF) testing solution.

This past weekend, CURA's Vice President of Sales joined leading clinicians, researchers, and industry professionals at the 57th Annual Conference of the American Society of Addiction Medicine (ASAM) in San Diego, California.Throughout the conference,

This past April, CURA Diagnostics proudly participated in two leading industry conferences: the Rx and Illicit Drug Summit and the Governor's Institute.For over 15 years, the Rx and Illicit Drug Summit has been a driving force in the fight against the

We are pleased to share that in February 2026, CURA's Clinical Consultant and Scientific Advisory Board Member, Dr. Peter Coleman, released his new book, Complete Freedom from Opioid Addiction: A Guide from a Recovering Physician.

CURA is proud to launch the Xpeedy®Oral Fluid Toxicology Solution at this year’s National Drug & Alcohol Screening Association Trade Show.From sample collection to rapid screening to confirmatory testing, this fully integrated solution is engineered to su

CURA is excited to be launching our new product line, Xpeedy® SPEctra™, at this year's ADLM exposition. This cutting-edge solution features a high-sensitivity, magnetic beads-based extraction kit and a fully automated method for LC/MS analysis. Increa

We are thrilled to announce the success of our recent Open House event, held on June 2, 2025! The event welcomed partners, clients, colleagues, and community members to experience a behind-the-scenes look at the cutting-edge technology, passionate team, a

CURA Diagnostics proudly helped kickoff Asian American and Pacific Islander (AAPI) Heritage Month for HALEON with a compelling keynote from CEO Jia He, who served as the event's Spotlight Speaker. Her participation marked a powerful beginning to the m

We are very pleased to work with a local non-profit, Daily Planet Health Services. Through a recent donation aimed at supporting their mission to provide accessible health service to individuals in need. At CURA Diagnostics, we understand that the fight a

CURA Diagnostics has had an incredible year, marked by significant accomplishments and exciting new partnerships. As we wrap up this year and look forward to an even stronger start to the next, we are thrilled to introduce our new Vice President of Sales,

November 4th, 2024 – As Transversal Therapeutics (CURA owned subsidiary company) pursues non-dilutive funding opportunities in the drug toxicology space, we are excited to announce that we have recently received the notice of allowance for our patent appl

September 17th, 2024– As CURA enters the latter half of the year, we are pleased to announce the successful completion of our Pre-A series funding round. CURA has raised over $4 million, led by a prominent asset management firm. Underscoring strong confid

CURA is dedicated to building and sustaining strong partnerships, with a primary focus on delivering outstanding customer service and ensuring client satisfaction. As we continue to grow, we've successfully established enduring relationships on a glob

CURA Diagnostics is thrilled to announce their new partnership with Mercedes Scientific. As a leader in laboratory distribution, Mercedes Scientific has established itself as a top player in the industry through collaborations with leading diagnostic comp

CURA Diagnostics is very excited to announce another significant achievement! We have implemented our complete solution in Kentucky-based laboratory.The Laboratory has not only passed its state inspection but has done so flawlessly, without a single defic